Highlights

  • Racura Oncology Limited (ASX: RAC) has had its CPACS abstract accepted for a poster presentation at the Global Cardio-Oncology Summit 2026 in Williamsburg, Virginia.
  • CPACS is a multicentre, open-label, two-part Phase 1 trial testing RC220 combined with doxorubicin in adults with advanced solid tumours.
  • The first cohort of three patients on RC220 at 40 mg/m2 and doxorubicin at 60 mg/m2 showed an acceptable safety profile with no dose-limiting toxicities, allowing escalation to 80 mg/m2.
  • RC220 is a proprietary formulation of (E,E)-bisantrene, which acts through G-quadruplex DNA and RNA binding to silence c-MYC in preclinical models.
  • CPACS is an early Phase 1 study; an acceptable initial safety profile does not establish efficacy, and encouraging preclinical results are not clinical proof.

Racura Oncology Limited (ASX: RAC) is a clinical-stage biopharmaceutical company whose stated mission is to "silence cancer". One of its programs addresses a problem that has shadowed cancer medicine for decades: the heart damage caused by some of the most effective chemotherapy drugs ever developed. Through a Phase 1 study known as CPACS, Racura is exploring whether its investigational agent RC220 can be safely combined with doxorubicin, a workhorse chemotherapy, in patients with advanced solid tumours.

This article examines the science behind that unmet need, explaining why anthracycline drugs such as doxorubicin are both indispensable and dangerous, why combination therapy is being investigated, and how RC220 fits in, framing Racura Oncology as attempting to address a long-standing oncology challenge, not as having solved it.

Inside the Announcement

According to Racura Oncology, its abstract titled "Cardioprotection and Anticancer Synergy (CPACS) - A Phase 1 Study of RC220 in Combination with Doxorubicin - Trial in Progress" has been accepted for a poster presentation at the Global Cardio-Oncology Summit 2026, which runs from 5 to 7 October 2026 in Williamsburg, Virginia, in the United States.

The company describes CPACS as a multicentre, open-label, two-part Phase 1 trial in adult patients with advanced solid tumours. Enrolment is ongoing in Australia and Hong Kong, and participation in South Korea is expected to commence. Part 1 is a Bayesian Optimal Interval, or BOIN, guided dose-escalation study of intravenous RC220 combined with doxorubicin at 60 mg/m2, preceded by monotherapy safety lead-in cycles of each agent. The primary objective is the safety and tolerability of the combination. Secondary objectives include the maximum tolerated combined dose, pharmacokinetics, anti-tumour efficacy and exploratory cardioprotection biomarkers. Part 2, following an interim review, is designed as a dose-expansion cohort to further assess safety, tolerability, preliminary anticancer activity and the protection of cardiac function after anthracycline exposure.

On results to date, and attributing these findings to the accepted abstract, Racura reports that the first cohort of three patients treated with RC220 at 40 mg/m2 and doxorubicin at 60 mg/m2, over up to five cycles, was reviewed by an independent Safety Review Committee. The combination was found to have an acceptable safety profile with no dose-limiting toxicity or other significant safety concerns, and the committee allowed escalation to the next RC220 dose level of 80 mg/m2. The abstract concludes that these initial safety findings support continued dose escalation, and that enrolment is ongoing.

Chief Executive Officer Dr Daniel Tillett has indicated that the acceptance highlights growing interest in RC220's potential to address cardiotoxicity, one of the key limitations of anthracycline-based cancer therapy, and that the study is evaluating whether RC220 can be safely combined with doxorubicin to enhance anticancer activity and reduce cardiac injury.

Background: Racura Oncology and RC220

Racura Oncology Limited, listed on the ASX under the code RAC, is a Phase 3 clinical-stage biopharmaceutical company based in Sydney. Its lead compound is (E,E)-bisantrene, a small molecule anticancer agent. Recent work indicates it acts primarily through binding to G-quadruplex DNA and RNA structures, which leads to potent silencing of the c-MYC gene, an important regulator of cancer growth. The compound has demonstrated therapeutic activity in cancer patients and has a well-characterised safety profile.

RC220 is a proprietary formulation of (E,E)-bisantrene developed by Racura. The company is advancing it across three clinical programs: a Phase 3 program in acute myeloid leukaemia, the HARNESS-1 Phase 1 trial combining RC220 with Tagrisso in mutant EGFR non-small cell lung cancer, and the CPACS Phase 1 program in solid tumours. CPACS is built specifically around the goal of delivering both cardioprotection and enhanced anticancer activity.

The Science of an Unmet Need in Anthracycline Chemotherapy

Doxorubicin, the drug at the centre of CPACS, belongs to a class of chemotherapies called anthracyclines, medicines that have been part of cancer treatment for generations and remain central to many regimens across a range of tumour types.

Why doxorubicin is so valuable

Anthracyclines are among the most effective cytotoxic agents in oncology. They work inside dividing cells to interrupt the processes cancer depends on to replicate, and they get results across many cancers. That is precisely why oncologists have been reluctant to abandon them, and why an anthracycline-containing regimen remains a backbone of care for many patients.

Why doxorubicin is also dangerous

The difficulty is that the very potency that makes doxorubicin valuable comes with a serious cost. As Racura notes, anthracyclines remain central to many anticancer regimens but their clinical use is limited by irreversible cardiotoxicity. In plain terms, the drug can damage the heart, and that damage does not simply reverse when treatment stops. The risk accumulates with total dose, so clinicians often cap how much anthracycline a person can receive across their lifetime.

This creates a genuine clinical dilemma. A drug that could keep working against a cancer may have to be withdrawn, not because it has stopped fighting the tumour, but because continuing it could harm the heart, leaving some survivors with lasting cardiac consequences. This is the long-standing challenge that cardio-oncology, the field hosting the summit where Racura's abstract appears, exists to tackle.

Why combination therapy is a rational response

One way researchers try to escape such a dilemma is through combination therapy. Rather than replacing an effective but toxic drug, the aim is to pair it with a second agent that shifts the overall balance of benefit and harm, letting the established drug keep working while blunting the side effect that limits it. This is the logic CPACS is built to test with RC220 and doxorubicin.

How RC220 is being positioned within that logic

RC220 brings a distinct mechanism to the table. As the underlying (E,E)-bisantrene, it has recently been shown to act through G-quadruplex DNA and RNA binding, which silences expression of the c-MYC oncogene in preclinical cancer models, an attractive anticancer strategy given how many cancers rely on c-MYC to grow.

In preclinical studies, and it is important to stress that these are preclinical findings only, RC220 combined with doxorubicin showed improved anticancer activity in human and murine tumour models. The same preclinical work found the combination reduced anthracycline cardiotoxicity in human cardiomyocytes and in multiple animal cardiac models, both murine and canine, and that RC220 at 40 mg/m2 was protective against doxorubicin-induced cardiotoxicity. These laboratory and animal results motivated the clinical program, but they are not evidence of clinical benefit in people. CPACS is designed to begin asking whether any of that preclinical promise translates into human patients, starting with the fundamental question of safety.

What It Could Mean for ASX: RAC

For Racura Oncology and ASX: RAC, acceptance of the CPACS abstract at an international cardio-oncology summit is a visibility milestone, placing the program in front of specialists in the exact field concerned with the problem it targets.

The early safety signal, as reported by the company, is a necessary first step, since a Phase 1 study can only keep escalating doses after clearing each safety review. Investors should nonetheless keep this in proportion: what has been shown so far is that a small first cohort tolerated the starting dose combination, not that the therapy works or protects the heart.

Limitations and Key Risks

CPACS is an early-stage Phase 1 trial, and the limitations of that stage are considerable. An acceptable initial safety profile in three patients does not establish clinical efficacy, and it does not demonstrate that RC220 prevents heart damage or improves survival. Preclinical findings, however encouraging, are not clinical proof; results in cardiomyocytes and animal models frequently fail to reproduce in humans.

Clinically, the combination must continue to prove safe at higher doses, and later cohorts may surface toxicities not seen at the starting level. Regulatory risk is inherent to any investigational drug: approval pathways are long and never guaranteed. Funding risk is a constant for clinical-stage biopharmaceutical companies, which typically consume cash well before generating revenue, and further capital may be required. Execution risk spans multicentre enrolment across Australia, Hong Kong and the planned South Korean sites, trial conduct and data quality. Commercialisation risk remains distant; Racura has said it is actively exploring partnerships, licence agreements and merger and acquisition opportunities, but nothing has been signed. Readers should treat every stage of this journey as uncertain.

What Investors May Watch Next

Grounded in what Racura has disclosed, several markers lie ahead. The most immediate is the October 2026 poster presentation at the Global Cardio-Oncology Summit. Beyond that, dose escalation to the 80 mg/m2 RC220 level and the safety findings from subsequent cohorts will indicate whether the program continues advancing as designed.

The commencement of enrolment in South Korea would broaden the trial's footprint. Further out, any interim review triggering the Part 2 dose-expansion cohort would be a structural step, as that phase is designed to look at preliminary anticancer activity and cardiac function measures. None of these events should be assumed to produce positive outcomes.

Conclusion

The story of RC220 and doxorubicin is, at its heart, about an old and stubborn trade-off in cancer care: a highly effective chemotherapy that can wound the very patients it helps. Racura Oncology (ASX: RAC) is attempting to attack that trade-off directly, pairing an established anthracycline with an agent whose distinct c-MYC-silencing mechanism has shown preclinical promise for both efficacy and cardiac protection. The CPACS trial has cleared its first safety checkpoint and earned a place at an international forum. Those are real, if early, steps, not a resolution. Whether Racura Oncology can turn a compelling scientific rationale into a proven clinical benefit remains an open question that only further data can answer.